Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 6.26% | |
| Drug Manufacturers - General | 32.98% | 8.52% | |
| Healthcare Plans | 13.44% | -0.47% | |
| Medical Devices | 12.76% | 6.77% | |
| Biotechnology | 11.57% | 0.22% | |
| Diagnostics & Research | 10.73% | -0.25% | |
| Medical Instruments & Supplies | 7.80% | 25.17% | |
| Medical Care Facilities | 2.95% | 15.61% | |
| Drug Manufacturers - Specialty & Generic | 2.81% | -0.17% | |
| Medical Distribution | 2.52% | 19.46% | |
| Health Information Services | 2.31% | 20.90% | |
| Pharmaceutical Retailers | 0.12% | -64.26% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 799.02 | 999.43 | 10.81% | | | | Buy | |
| 601.52 | 625.10 | 8.33% | | | | Buy | |
| 154.12 | 175.98 | 5.60% | | | | Buy | |
| 179.62 | 208.90 | 4.78% | | | | Buy | |
| 100.81 | 133.43 | 3.89% | | | | Buy | |
| 117.28 | 130.24 | 3.07% | | | | Buy | |
| 531.25 | 657.43 | 3.06% | | | | Buy | |
| 542.65 | 539.24 | 2.91% | | | | Buy | |
| 239.37 | 288.34 | 2.60% | | | | Buy | |
| 277.98 | 335.10 | 2.25% | | | | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 146.50 | 39.816B | 0.09% | | |
| 270.74 | 20.549B | 0.10% | | |
| 99.17 | 7.244B | 0.35% | | |
| 141.49 | 7.086B | 0.45% | | |
| 60.78 | 4.783B | 0.40% | |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 214.34 | 45.697B | 0.30% | | |
| 90.41 | 45.697B | 0.30% | | |
| 136.05 | 20.549B | 0.10% | | |
| 97.23 | 14.589B | 0.80% | | |
| 96.88 | 14.589B | 0.80% | |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
RatingPrice TargetAnalyst Report: Moderna, Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetAnalyst Report: AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
RatingPrice TargetAnalyst Report: Sanofi
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
RatingPrice Target
